F0024
/ Shanghai Fudan-Zhangjiang
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
March 10, 2025
F0024-101: A Study of FDA018-ADC in Patients with Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=78 | Active, not recruiting | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer
September 26, 2024
FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
(clinicaltrials.gov)
- P3 | N=350 | Recruiting | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
August 26, 2024
Fudan Zhangjiang (688505.SH): The first patient was enrolled in the Phase III clinical trial of FDA018 antibody conjugate for injection for the treatment of triple-negative breast cancer [Google translation]
(Sina Corp)
- "Fudan Zhangjiang...announced that the first subject has been enrolled in the Phase III clinical study of the company's injectable FDA018 antibody conjugate...for the treatment of triple-negative breast cancer (TNBC)...recently."
Trial status • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
July 25, 2024
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
(clinicaltrials.gov)
- P3 | N=350 | Not yet recruiting | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Metastases • New P3 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
April 25, 2024
Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
(ASCO 2024)
- P1 | "Background: F0024 is an antibody-drug conjugate (ADC) targeting Trop-2, an intracellular calcium signaling transducer overexpressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. In this first-in-human study of F0024, treatment was generally well tolerated and MTD was not yet reached up to 12 mg/kg. F0024 demonstrated encouraging preliminary antitumor activity in heavily pretreated TNBC pts, especially in 10 and 12 mg/kg. Clinical trial information: NCT05174637."
Clinical • Metastases • P1 data • Anemia • Breast Cancer • Febrile Neutropenia • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer
January 03, 2022
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=78; Recruiting; Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Clinical • New P1 trial • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer
April 22, 2021
Fudan-Zhangjiang Bio’s anti-Trop2 ADC under trial review in China
(GBI Health)
- "China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd’s (01349.HK:688505.SH) clinical trial filing for FDA018, an anti-trophoblast cell-surface antigens2 (TROP2) antibody drug conjugate (ADC), has been accepted for review by the National Medical Products Administration. The drug, filed as a Category 1 therapeutic biologic product, will be assessed as a treatment for solid tumors."
Non-US regulatory • Oncology • Solid Tumor
1 to 7
Of
7
Go to page
1